Cipla acquires brand, trademark for anti-diabetic drug Vysov in India

Cipla Ltd, a homegrown pharma major, has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for Indian market from Novartis, stated by Cipla on Monday.  However, the acquisition amount has not been disclosed. 

The company disclosed in a regulatory filing that Cipla has been co-marketing Vildagliptin with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin).

"Owing to the increased affordability of Vildagliptin it is more accessible for better management of the disease. Cipla's acquisition of the trademark rights of Vysov will enable us to contribute to easier access of the drug in India," Cipla Executive Vice-President & Head India Business Nikhil Chopra said.

The company said, in India, the products have witnessed a strong demand for last couple of years and are currently unavailable across the country. Vildagliptin is backed by strong clinical data and is therefore a widely prescribed antidiabetic medicine for adults with type-2 diabetes mellitus, it added.

According to the IQVIA MAT data of November 2019, the market size of Vildagliptin stood at Rs 818 crores (US$ 117.04 million), the company said.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.